



PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 5 : G01N 33/564, 33/53, A61K 39/00	A1	(11) International Publication Number: WO 90/07117 (43) International Publication Date: 28 June 1990 (28.06.90)
(21) International Application Number: PCT/US89/05570 (22) International Filing Date: 8 December 1989 (08.12.89) (30) Priority data: 283,633 13 December 1988 (13.12.88) US 427,051 25 October 1989 (25.10.89) US (71) Applicant: UNIVERSITY OF FLORIDA [US/US]; 223 Grinter Hall, Gainesville, FL 32611 (US). (72) Inventors: ATKINSON, Mark, A. ; 8420 S.W. 52nd Place, Gainesville, FL 32608 (US). MACLAREN, Noel, K. ; 1608 S.W. 58th Avenue, Gainesville, FL 32608 (US). KASTER, William ; 8123 S.W. 47th Place, Gainesville, FL 32608 (US).	(74) Agents: SALIWANCHIK, David, R. et al.; Saliwanchik & Saliwanchik, 2421 N.W. 41st Street, Suite A-1, Gaines- ville, FL 32606 (US). (81) Designated States: AT (European patent), AU, BE (Euro- pean patent), CH (European patent), DE (European pa- tent), DK, ES (European patent), FI, FR (European pa- tent), GB (European patent), HU, IT (European patent), JP, KR, LU (European patent), NL (European patent), NO, SE (European patent), SU. Published <i>With international search report. Before the expiration of the time limit for amending the claims and to be republished in the event of the receipt of amendments.</i>	
(54) Title: METHODS AND COMPOSITIONS FOR THE EARLY DETECTION AND TREATMENT OF INSULIN DE- PENDENT DIABETES MELLITUS (57) Abstract The subject invention concerns a novel process for the early detection of insulin dependent diabetes (IDD). The novel pro- cess described here enables the detection of the onset of IDD before clinical symptoms appear. The novel process involves the de- tection, in a sample of biological fluid, of an autoantibody which is highly specific to individuals who will later develop the clini- cal manifestations of IDD. Novel treatments for IDD are also described.		

DESCRIPTIONMETHODS AND COMPOSITIONS FOR THE EARLY DETECTION AND TREATMENT
OF INSULIN DEPENDENT DIABETES MELLITUS

5

Background of the Invention

Diabetes is a major public health problem. As reported by the 1987 report of The National Long-Range Plan to Combat Diabetes of the National Diabetes Advisory Board, six million persons in the United States are known to have diabetes, and an additional 5 million have the disease which has not yet been diagnosed; each year, more than 500,000 new cases of diabetes are identified. In 1984, diabetes was directly causal in 35,000 American deaths and was a contributing factor in another 95,000.

Ocular complications of diabetes are the leading cause of new cases of legal blindness in people ages 20 to 74 in the United States. The risk for lower extremity amputation is 15 times greater in individuals with diabetes than in individuals without it. Estimates suggest that persons with diabetes undergo over one-half of the approximately 125,000 amputations performed annually in the United States.

Kidney disease is a frequent and serious complication of diabetes. Approximately 30 percent of all new patients in the United States being treated for end-stage renal disease have diabetes. This percentage is increasing at a rate of approximately 2 percent annually; therefore, within the next decade, diabetes-related kidney disease will account for more than one-half of all enrollees in the End-Stage Renal Disease Program.

Individuals with diabetes are also at increased risk for periodontal disease. Periodontal infections advance rapidly and lead not only to loss of teeth but also to compromised metabolic control. Women with diabetes risk serious

complications of pregnancy. Current statistics suggest that the mortality rates of infants of mothers with diabetes is approximately 7 percent.

5 The economic burden of diabetes is enormous. Each year, patients with diabetes or its complications spend 24 million patient-days in hospitals. A conservative estimate of total annual costs attributable to diabetes is at least \$24 billion (American Diabetes Association est., 1988); the full economic impact of this disease is even greater because additional medical expenses often are attributed to the specific complications of diabetes rather than to diabetes itself.

10 Diabetes is a chronic, complex metabolic disease that results in the inability of the body to properly maintain and use carbohydrates, fats, and proteins. It results from the interaction of various hereditary and environmental factors and is characterized by high blood glucose levels caused by a deficiency in insulin production or an impairment of its utilization. Most cases of diabetes fall into two clinical types: insulin-dependent diabetes mellitus (IDDM or IDD) and non-insulin-dependent diabetes mellitus (NIDDM or NIDD). Each type has a different prognosis, treatment, and cause.

15 Approximately 5 to 10 percent of diabetes patients have IDD, formerly known as juvenile diabetes because of its frequent appearance early in life, usually in childhood or adolescence. IDD is characterized by a partial or complete inability to produce insulin. Patients with IDD would die without daily insulin injections to control their disease.

20 Few advancements in resolving the pathogenesis of diabetes were made until the mid-1970s when evidence began to accumulate to suggest that IDD had an autoimmune etiopathogenesis. It is now generally accepted that IDD results from the chronic autoimmune destruction of the insulin producing pancreatic beta cells. Lymphocytes and other inflammatory cells have been observed within the islets of Langerhans in newly diagnosed IDD patients and have been found preferentially in regenerating islets composed of beta cells rather than those of

other cell types. This active immunological process is associated with a variety of autoantibodies to beta cell cytoplasmic and membrane antigens, insulin, and insulin receptors.

Thus, IDD is a disease which is replete with autoantibodies. These include islet cell autoantibodies of the cytoplasmic type (ICA) (Gepts, W. and J. De Mey [1978] *Diabetes* 27(Suppl. 1):251-261); islet cell surface autoantibodies (ICSA) (Herold, K.C., A.H.J. Huen, A.H. Rubenstein, and A. Lernmark [1984] In: *Immunology in Diabetes*, D. Andreani, U. De Mario, K.F. Federlin, and L.G. Heding, eds., pp. 105-120, Krimpton Medical Publications, London); insulin autoantibodies (IAA) (Gorsuch, A.N., K.M. Spencer, J. Lister, E. Wolf, G.F. Bottazzo, and A.G. Cudworth [1982] *Diabetes* 31:862-866) and the possible antiidiotypic insulin receptor autoantibodies (Ins.R.A.) (Maron, R., D. Elias, M. de J. Bartelt, G.J. Bruining, J.J. Van Rood, Y. Shechter, and I.R. Cohen [1983] *Nature* 303:817-818). In 1982 it was reported that antibodies to a 64,000 M_r islet cell antigen were detected in IDD patients (Bækkeskov, S. et al. [1982] *Nature* 298:167-169). In a subsequent publication, Bækkeskov et al. reported the 64,000 M_r antibodies associated with the IDD in the BB rat model (Bækkeskov, S. et al. [1984] *Science* 224:1348-1350). Later, a follow-up study investigated patients who were related to individuals with IDD and, thus, were known to be at risk for developing the disease (Bækkeskov, S. et al. [1987] *J. Clin. Invest.* 79:926-934). The results of this later study suggested that the 64,000 M_r antibodies may be present in some IDD patients before the manifestation of clinical symptoms. However, in that same study, Bækkeskov et al. reported that the function of the 64,000 M_r protein was unknown and that the data was inconclusive as to whether or not 64,000 M_r antibodies were present before a decrease in β -cell function commenced.

Other antibodies to various non-beta cell specific molecules have been reported with an increased prevalence in IDD patients. These include antibodies

to tubulin, single stranded and double stranded DNA, gastric parietal cells, intrinsic factor, thyroid peroxidase enzymes, and thyroglobulin. IDD patients have signs of polyclonal activation of B-lymphocytes, and the increased antibody titers to various antigens may be the result.

5 Furthermore, studies during the past decade have shown that patients with IDD have genetic markers, called histocompatibility antigens, that are associated with susceptibility to IDD. Because these genetic susceptibility markers are necessary but not sufficient for the development of IDD, it appears that some additional, as yet unknown, environmental factors could be required to initiate
10 the destruction of the beta cells and the development of diabetes. Environmental factors, either viruses or chemical agents, may alter the beta cells to permit their immunologic destruction in genetically susceptible individuals. Therefore, identification of the prediabetic state in diabetes is essential in efforts to prevent the development of the disease. Perhaps the single most important advance of
15 the past two decades in diabetes research has been recognition that autoimmune destruction of beta cells takes months or years to reach completion. Whereas currently the clinical diagnosis of diabetes is almost never made until the destructive process is nearly complete and insulin injections are required to prevent death, intervention before the insulin-producing cells have been
20 irreversibly destroyed can provide a strategy to prevent progression of diabetes and its complications.

It is crucial, therefore, to find a means of accurately predicting the onset of IDD before the disease has progressed to the clinical stage.

25 Although many biological markers have been associated with IDD, until now, none of these markers have been shown to be present uniformly before the onset of the clinical symptoms of the disease (Atkinson et al. [1988] Diabetes 37[suppl. 1] 98A). Such early presence is essential for a compound to qualify as a useful predictive test for the disease. However, early presence alone is not

5 sufficient for an accurate early detection method; a predictive test based on the presence or absence of a particular marker is valuable only if the predictive marker is present only in those who will get IDD, and not present in those who will not. Because the treatments for diabetes, as well as the psychological impacts of the disease, can have a profound effect on the health of the diagnosed individual, it is crucial to develop a predictive test which is specific and, thus, provides very few false positives.

10 It is also crucial to identify a predictive test which can recognize the onset of the disease years before the clinical symptoms appear. This early detection provides an opportunity for treatments which can forestall or prevent the serious health problems associated with the clinical stages of IDD. For example, nonspecific immunosuppression trials with drugs such as Cyclosporin A, azathioprine and steroids have been undertaken in newly diagnosed patients. Over the first year of their use, a limited number of remissions have been
15 obtained, but these patients are never restored to normal since pancreatic beta cells have only limited regenerative capacity, and treatments begun at the time of diagnosis are most often too late.

20 Until now, no suitable predictive test for IDD meeting these requirements has been found. Although many autoantibodies have been associated with the disease, research into identifying uniformly predictive autoantibodies has not been successful. For example, as early as 1976, autoantibodies have been described which reacted with the cytoplasm of the glucagon-secreting (alpha) cells (ACA) of the islet (Bottazzo, G.F., and R. Lendrum [1976] Lancet 2:873-876). Because autoantibodies against endocrine glands are sometimes found to precede or
25 accompany the clinical onset of disease, it was thought that ACA could be a predictive marker for deficiency of the islet hormone, glucagon. Unfortunately, subsequent research revealed that ACA did not appear to be associated with defective alpha cell function, with IDD, or with any identifiable pancreatic

pathology (Winter, W.E., N.K. Maclaren, W.J. Riley, R.H. Unger, M. Neufeld, and P.T. Ozand [1984] Diabetes 33(5):435-437).

5 Similar research into the predictive value of other antibodies associated with the pancreas and the clinical stages of IDD have not produced a suitable means for early detection of the disease. For example, both insulin autoantibodies (IAA) and islet cell autoantibodies (ICA) have been found to be present in many newly diagnosed patients. But neither IAA nor ICA alone has been shown to be uniformly present far in advance of the clinical stages of IDD, specifically in non-diabetic relatives at risk for IDD, nor correlated strongly with 10 the early onset of the disease. Thus, neither provides a predictive test with near absolute specificity and sensitivity.

Therefore, there exists a substantial and long-felt need for a more accurate means of detecting IDD in its early stages prior to the onset of clinical symptoms and the requirement of insulin therapy.

15

Brief Summary of the Invention

The invention described here concerns a novel means of accurately detecting the early stages of Insulin Dependent Diabetes Mellitus (IDD). Specifically, IDD can be detected before a significant loss of β -cell function. Also 20 described are means of treating IDD in its initial stages.

In particular, it has been found that autoantibodies, designated 64KA, are present up to several years before the clinical manifestations of IDD are observed. The early detection of this potentially devastating disease would facilitate the administration of treatments which would not be effective during 25 the later stages of the disease when irreversible damage is extensive.

The 64KA can be used alone, or in combination with other autoantibodies such as ICA and IAA which are known to be associated with IDD, to detect and predict the onset of IDD. The 64KA described here are highly disease specific

for IDD. The 64KA have been found to be present uniformly in children and young adults studied months to years prior to their onset of IDD. The 64KA test was found to predict the onset of IDD when other antibodies associated with the disease could not.

5 The protein antigens reactive with the 64KA are also revealed to be useful in the treatment of IDD. Described here as part of the subject invention are novel means for halting or slowing the onset of IDD. The novel means of treatment involves the construction of novel hybrid beta cell 64K proteins -- toxin products which are capable of disabling immunological mediators involved in the
10 pathogenesis of IDD.

 A further aspect of the invention is the use of 64KA to diagnose and prevent impending destruction of pancreas islet cell transplants by minimizing immune-related destruction and rejection of the new pancreas by administration of the 64K hybrid toxin molecules. Additionally, the invention concerns the use
15 of anti-idiotypic antibodies to the 64KA as a means of intervention therapy.

Detailed Description of the Invention

 The invention described here relates to the use of a 64K autoantibody as an accurate and specific early indicator of the onset of IDD. The identification
20 of 64KA as a useful predictive marker for IDD resulted from exhaustive biochemical research focusing on a multitude of compounds associated with IDD. The high specificity of 64KA for IDD, as well as the frequent presence of 64KA in individuals years before the onset of IDD, were both unexpected. These attributes of 64KA make it useful as a means of early detection of IDD.

25 In order to ascertain whether specific entities are valid predictors of the onset of IDD, it is necessary to determine whether these entities are present before clinical symptoms of diabetes occur. This prediabetic period has been difficult to study because large numbers of high risk relatives of affected

probands must be screened for circulating autoantibodies to identify the susceptible individuals, and long periods of observations are necessary to document the natural history of the beta cell failure in the disease. Therefore, animal models have been used to augment and further confirm data obtained for human tests.

The non-obese diabetic (NOD) mouse is a useful animal model for human IDD. Analysis of the NOD mouse provides important insights into the sequence of pathogenic events and leads to an understanding of the nature of the target islet cell autoantigens involved in the autoimmune process. Another important model for IDD is the Biobreeding (BB) rat. The subject invention was discovered as a result of research and studies involving humans, BB rats, and NOD mice.

It was found that in IDD of man and the BB rat model, islet cell autoimmunities are associated with autoantibodies to a beta cell protein of relative molecular mass (M_r) 64,000 (64K). It has also been determined that sera from newly-diagnosed NOD mice similarly contain an autoantibody that immunoprecipitates the 64K antigen from detergent lysates of ^{35}S methionine labelled murine islet cells (Atkinson, M., and N.K. Maclaren [1988] Diabetes 38:1587-1590). In NOD mice the autoantibody was detectable by the time of weaning, it disappeared within weeks after diabetes onset, and was absent in older non-diabetic mice as well as all of three non-diabetes-prone control strains tested.

In humans, the 64KA were present before clinical diagnosis in 96% of individuals who subsequently were under the age of 35 at IDD onset. The 64KA were found to be predictably present well in advance of the clinical manifestations of IDD. Also, the presence of 64KA was found to be highly specific to IDD; unlike IAA or ICA, 64KA has not been observed in individuals who are not at high risk, or increased risk, to develop IDD.

Materials and Methods

Islet Cell Preparations

Human pancreatic islets were isolated from cadaveric pancreases as previously reported (Diabetes 37:413-420, 1988). All batches of islets were maintained in vitro in supplemented media CMRL 1066. A mean of $84,946 \pm 11,061$ ($x \pm \text{SEM}$, $n=12$) isolated human islets per batch were obtained with a mean islet purity of $91.2 \pm 2.3\%$, and an insulin content of 0.4 ± 0.1 mU insulin per islet. Perfusion testing of KREBS with alternating glucose concentrations of 60 mg/dl - 300 mg/dl gave a mean insulin stimulation index of 4.68 ± 0.66 (G300/G60). All batches were labeled within 7 days.

Metabolic Labeling of Islet Cells

Following a minimum of 36 hours of in vitro culture (6000 islets/50 ml RPMI 1640 medium supplemented with 16 mM glucose, 20 mM HEPES, 100 uU/ml penicillin, 100 $\mu\text{g/ml}$ streptomycin, 2% (v/v) normal human serum, 37°C, 95% air/5% CO_2), the islets were reseeded and incubated for 15 minutes in supplemented RPMI 1640 medium (1000 islets/ml) which was deficient in methionine. The cells were then incubated for 5 hours at 37°C (95% air/5% CO_2) in methionine free medium (1000 islets/ml) to which ^{35}S methionine (> 500 Ci/mmol) had been added at a concentration of 0.5 mCi/ 1×10^3 islet cells. The cells were next incubated with supplemented methionine containing (0.5 mM) RPMI 1640 medium (1000 islets/ml) for 30 minutes, washed twice (200 x g, 5 minutes) in buffer containing 20 mM Tris (pH 7.4), 150 mM NaCl, 100 KIE/ml aprotinin, and 2 mM phenylmethyl sulfonyl fluoride (PMSF), and then snap frozen (-80°C) until their detergent extraction.

Immunoprecipitation of 64K Autoantigen

The islet cells were lysed in the above buffer containing 2% TRITON™X-114. The insoluble material was removed by ultracentrifugation (100,000 x g, 30

minutes, 4°C). The lysate was then separated into aqueous, sucrose, and detergent phases prior to immunoprecipitation (Bordier, C. [1981] J. Biol. Chem 256:1064-1067). The lysate was incubated with normal control human serum (10 μ l per 100 μ l supernatant, 1 hour, 4°C) followed by adsorption to an excess of protein A Sepharose CL-4B (100 μ l swollen protein A Sepharose to 25 μ l sera). Aliquots (100 μ l containing 5-10 x 10⁶ cpm) of unbound (pre-cleared) lysate were incubated with 25 μ l of test sera (either IDD or control) for 18 hours (4°C). Detergent extracts from 1000 islets for each serum sample tested was used. To each assay tube, 100 μ l of pre-swollen protein A Sepharose CL-4B were added, and the reaction mixture was incubated for 45 minutes (4°C). The protein A Sepharose CL-4B was then washed five times by centrifugation (200 x g, 10 seconds) in 0.5% TRITONTMX-114 buffer and once in ice cold double distilled water (200 x g, 30 seconds). Bound proteins were eluted and denatured by boiling for 3 minutes in sample buffer containing 80 mM Tris (pH 6.8), 3.0% (w/v) sodium dodecyl sulfate (SDS), 15% (v/v) sucrose, 0.001% (v/v) bromphenyl blue, and 5.0% (v/v) β -mercaptoethanol. The Sepharose beads were removed by centrifugation (200 x g, 1 minute) and the supernatant electrophoresed through discontinuous SDS 10% polyacrylamide separating gels, followed by Coomassie Brilliant Blue staining and fluorography using Enhance (New England Nuclear, Boston, MA).

ICA Analysis

ICA were assayed by indirect immunofluorescence on blood group O cryocut pancreatic sections as described in (Neufeld, M. N. Maclaren, W. Riley, D. Lezotte, H. McLaughlin, J. Silverstein, and A. Rosenbloom [1982] Diabetes 29:589-592). All results were read on coded samples, with control negative and positive sera in each batch. Sera were considered positive if immunofluorescence of the tissue was observed within the pancreatic islets. Positive results are those in which the autoantibody exceeds a concentration (or titer) of 10 Juvenile

Diabetes Foundation (JDF) units, as defined by the Immunology of Diabetes Workshops (IDW) and standardized by a worldwide ICA proficiency testing program administered by Noel K. Maclaren.

Insulin autoantibody binding procedure

5 The RIA method used to detect IAA was modified to maximize sensitivity without loss of specificity for IDD. Mean serum insulin binding was calculated from sera obtained from 94 non-diabetic Caucasian children and lab personnel (mean age 13.7 ± 7.7 yrs., 51 males/43 females) lacking a family history of IDD. None of these control individuals were positive for ICA. Optimal results were
10 found using moniodinated human insulin radiolabeled with ^{125}I at the A14 position at a concentration of 0.15 ng/ml. More recently, improved specificity of the assay has been achieved by determination of specific binding which was displaceable through the addition of excess unlabeled insulin.

IVGTT procedure

15 In order to investigate the insulin response to glucose stimulation, an intravenous glucose tolerance test (IVGTT) was performed (Srikanta, S., O.P. Ganda, G.S. Eisenbarth, and J.S. Soeldner [1983] N. Engl. J. Med. 308:322-325) with the dose of administered glucose at 0.5 g/Kg given intravenously precisely over 2-4 minutes. Serum samples were collected at -10, 1, 3, 5, 10, 15, 30, and
20 60 minutes post glucose infusion. Insulin deficiency was defined when the insulin level at 1 minute and 3 minute together were < 3rd percentile for a control population of ICA negative non-IDD individuals ($n=150$, Age 20.3 ± 10.2 years, range 2 to 59 years). For this analysis, insulin values less than $70 \mu\text{IU/ml}$ (< 3rd percentile for the 150 controls) were considered to be insulinopenic.

25 HLA DR typing

 HLA DR typing was performed as adapted from the method described by Van Rood and Van Leuwen (Van Rood, J.J., A. Van Leuwen, and J.S. Ploem

[1976] Nature 262:795-797). Standard reference antisera were used for typing.

Following are examples which illustrate procedures, including the best mode, for practicing the invention. These examples should not be construed as limiting. All percentages are by weight and all solvent mixture proportions are by volume unless otherwise noted.

Statistical analysis included both Chi-square analysis after the Yate's correction factor was applied, and Fisher's exact test (Snedecor, T.N. and W.G. Cochran [1967] Statistical Methods. Iowa State University Press, Ames, Iowa).

Example 1 - Association of 64KA with IDD

Five groups of individuals were selected for the 64KA studies. There were 31 newly diagnosed patients with IDD, defined according to the established National Diabetes Data Group (NDDG) criteria (National Diabetes Data Group [1979] "Classification and Diagnosis of Diabetes Mellitus and Other Categories of Glucose Intolerance," Diabetes 28:1039-1057). Also studied were 26 nondiabetic controls who lacked ICA and any known family history of autoimmune disease; 40 nondiabetic ICA and IAA lacking relatives of the aforementioned newly-diagnosed patients; 36 nondiabetic but ICA positive individuals of whom 28 were first degree relatives of probands with IDD, 4 were apparently healthy normal controls, and 4 were patients with Autoimmune Addison's disease or thyroiditis; 5 ICA negative but high titer IAA positive children who were unaffected relatives of probands with IDD, and 28 additional individuals whose sera had been collected prior to their documented onset of IDD.

The above patients were obtained through two ongoing prospective ICA screening population studies of more than 5000 first degree relatives of IDD probands, and 8200 normal control individuals of which approximately 5000 were

school children. All sera were stored at 20°C from 1 week to 7 years prior to autoantibody analysis.

The 64KA was found to be extremely disease specific in that it was present in 84% of newly diagnosed IDD patients, and was completely absent from the control population tested ($p < 0.0001$).

Example 2 – 64KA as Predictor of IDD

In order to analyze the capacity of 64KA to actually predict the onset of IDD, serum samples from 28 individuals were analyzed for 64KA. The serum samples had been taken prior to the onset of any clinical manifestations of IDD. Each of the 28 individuals developed clinical symptoms of IDD at some later point in their life. Of these 28 individuals, 25 developed clinical symptoms before age 35.

It was found that the 64KA were present in 24 of the 25 (96%) of the individuals who were under age 35 at the onset of clinical IDD. The serum samples tested from these individuals had been taken anywhere from 3 months to 7 years (mean 27 months) prior to the clinical onset of IDD. The presence of 64KA occurred as early as 7 years prior to the onset of clinical symptoms.

The same serum samples were also tested for the presence of ICA and IAA. In contrast to the 64KA which was present in 82% of all cases, ICA was present in 22 out of 28 (78%) samples, and IAA were present in only 13 out of 27 (48%) of the samples. These results are presented in Tables 1 through 4. Clearly, the predictive value of 64KA for IDD was the best of all three autoantibodies.

Table 1. Frequency of 64,000 Mr Autoantibodies.

	<u>Group</u>	<u>n</u>	<u>64KA</u>	<u>ICA</u>
5	Control	26	0(0)	0(0)
	Newly Diagnosed IDD	31	26(84)	25(81)
10	ICA-/IAA- Relative	40	1(2)	0(0)
	ICA+ Relative	28	23(82)	28(100)
15	ICA+ others	8	7(87)	8(100)
	ICA-/IAA+ <5 yr age	5	4(80)	0(0)

Table 2. Summary of the Findings of Non-diabetic Patients at Risk for IDD
Because of ICA Positivity

Sex	Age	HLA-DR	Ascertainment	IDD Associated Autoantibodies			Plasma insulin IVGTT (1+3min(%tile))
				ICA*	64K	IAA	
M	6	3,-	IDD family study	80	+	-	144 (40)
M	9	3,1	IDD family study	40	+	-	57 (<1)
F	11	3,4	IDD family study	80	+	+	ND
M	11	3,4	IDD family study	80	+	+	105 (20)
F	12	4,3	IDD family study	40	+	-	194 (60)
F	13	2,4	IDD family study	40	+	+	62 (<3)
M	17	3,4	IDD family study	20	+	-	67 (<3)
M	20	2,4	IDD family study	40	+	+	58 (<1)
F	29	3,4	IDD family study	40	+	-	57 (<1)
F	30	3,-	IDD family study	160	+	-	82 (10)
F	33	3,8	IDD family study	20	+	-	125 (30)
F	34	3,4	IDD family study	40	+	-	167 (50)
M	44	4,1	IDD family study	20	-	-	ND
F	10	4,8	IDD family study	360	+	-	98 (20)
F	38	4,-	IDD family study	20	+	+	71 (5)
M	7	4,8	IDD family study	40	+	+	114 (25)
M	7	3,4	IDD family study	20	+	+	116 (25)
M	10	4,-	IDD family study	160	+	+	52 (<1)
F	10	5,9	IDD family study	20	+	+	128 (30)
F	43	3,1	IDD family study	80	-	-	293 (70)
F	13	1,3	IDD family study	80	-	-	100 (20)
M	5	2,4	IDD family study	40	+	-	125 (30)
F	39	4,-	IDD family study	80	+	+	112 (25)
M	11	3,4	IDD family study	40	+	+	56 (<1)
F	35	4,7	IDD family study	40	+	-	420 (90)
M	43	3,7	IDD family study	160	-	-	ND
F	38	3,4	IDD family study	20	-	-	184 (60)
F	26	ND	IDD family study	40	+	+	ND
M	8	3,4	School study	160	+	+	67 (<3)
M	10	3,4	School study	160	-	-	268 (75)
F	13	4,6	School study	40	+	-	67 (<3)
M	11	3,4	School study	320	+	+	124 (30)
M	16	3,4	Addison's/Thyroiditis	160	+	-	ND
M	32	3,4	Addison's/Thyroiditis	80	+	-	197 (60)
F	41	3,4	Addison's/Thyroiditis	320	+	+	69 (<3)
M	12	3,4	Addison's/Thyroiditis	160	+	-	149 (40)

* JDF units

Table 3. Summary of Findings of the First Serum Sample Available from Patients Tested Prior to their Development of IDD

Sex	HLA-DR	Age at Onset	Ascertainment	Prediabetic Period (mo)	IDD Associated Autoantibodies		
					ICA*	64K	IAA
M	3,3	5	IDD family study	9	—	+	—
M	4,6	10	IDD family study	34	20	+	+
F	4,7	11	IDD family study	34	40	+	+
M	3,3	12	IDD family study	8	40	+	—
F	4,6	15	IDD family study	3	80	+	—
M	3,4	15	IDD family study	19	80	+	+
M	3,4	17	IDD family study	14	—	+	—
M	3,4	19	IDD family study	3	40	+	—
M	ND	21	IDD family study	32	80	+	—
F	4,—	33	IDD family study	14	10	+	+
F	4,5	38	IDD family study	2	80	—	—
M	3,4	42	IDD family study	42	80	+	+
M	4,6	5	IDD family study	30	—**	—**	+
M	3,4	15	IDD family study	6	—	+	+
M	3,4	30	IDD family study	13	160	+	ND
M	ND	4	IDD family study	3	20	—	—
M	6,1	33	IDD family study	14	—**	+	—
F	4,6	37	IDD family study	3	80	—	—
F	3,4	7	gluc intol	11	+(NT)	+	+
M	4,4	15	gluc intol	2	80	+	+
F	3,6	17	gluc intol	2	20	+	—
M	2,3	18	gluc intol	12	40	+	—
M	ND	27	gluc intol	6	40	+	+
F	2,3	40	gluc intol	19	+(NT)	—	—
F	1,4	9	school study	3	40	+	+
F	3,4	12	school study	44	320	+	+
F	3,3	24	Graves disease	72	—**	+	—
F	1,4	14	Thyroiditis	75	+(NT)	+	+

22/28 23/28 13/27
(78%) (82%) (48%)

NT = Not JDF Titrated

ND = Not Determined

* = JDF units

** = Converted to Autoantibody Positivity at a Subsequent Sample Date

Table 4. Summary of the Findings of Non-diabetic Patients at Risk for IDD Because of IAA Positivity

<u>Sex</u>	<u>Age</u>	<u>HLA-DR</u>	<u>Ascertainment</u>	<u>IDD Associated Autoantibodies</u>			<u>Plasma insulin IVGTT (1+3min(%tile)</u>
				<u>ICA</u>	<u>64K</u>	<u>IAA</u>	
F	2	4,5	IDD family study	—	+	+	129 (40)
M	3	2,1	IDD family study	—	+	+	27 (<1)
F	5	ND	IDD family study	—	+	+	ND
M	0.5	1,6	IDD family study	—	+	+	342
F	3	ND	IDD family study	—	—	+	ND

Example 3 — Association of 64KA with IDD in NOD Mice

Recently, two types of animals (the BB rat and NOD mouse) have been developed that can serve as models for studying human IDD. The use of animal models to evaluate predictors of IDD is very valuable because the pre-diabetic period is difficult to study due to the large numbers of high risk relatives of affected probands which must be screened for circulating autoantibodies in order to identify the susceptible individuals, and because of the long periods of observations which are necessary to document the natural history of beta cell failure in the disease. The NOD mouse and the BB rat provide important insights into the sequence of pathogenic events involved in human IDD. Analysis of these animals can also help lead to an understanding of the nature of the target islet cell autoantigens involved in the autoimmune process. We therefore studied NOD mice and BB rats for their possible 64K autoantibodies, both prior to and after IDD onset.

Sera were obtained from both male and female NOD and control (BALB/c, C57BL/6, C2H/HeJ) strains of mice of various ages. Diagnosis of IDD in NOD mice was characterized by thirst and weight loss, and persistent

hyperglycemia of more than 240 mg/dl. For health maintenance, all diabetics received daily insulin doses of protamine-zinc insulin (Eli Lilly, Indianapolis, IN) at 0.5 to 2.0 units daily.

BALB/c islets were isolated according to the method of Brundstedt (Brundstedt, J., Nielsen, J.H., Lernmark, A., and the Hagedorn Study Group: in Methods in Diabetes Research, J. Larner, S.L. Pohl, Ed. [John Wiley & Sons, New York, 1987]), and labeled with ^{35}S methionine. Islet cells were washed twice (4°C) in supplemented RPMI 1640 (GIBCO, New York) medium (2.0% fetal calf serum, 100 units/ml penicillin, 100 $\mu\text{g}/\text{ml}$ streptomycin), followed by one wash in buffer containing 20mM Tris (pH 7.4), 150mM NaCl, 1000 KIE/ml trasytol and 2mM PMSF. Cells were then lysed in the above buffer containing 1% Nonidet P-40 (NP-40)(v/v). Insoluble material was removed by ultracentrifugation (100,000 x g, 30 min). The lysate was incubated with normal mouse serum (Balb/c) (10 μl per 100 μl supernatant, 1 h, 4°C) followed by adsorption to an excess of protein A Sepharose CL-4B. This incubation/adsorption procedure was repeated 3 times. Aliquots (100 μl) of unbound (pre-cleared) lysate were incubated with 25 μl of either NOD or control sera for 18 h (4°C). To each assay tube, 100 μl of pre-swollen protein A Sepharose CL-4B were added, and the reaction mixture was incubated for 45 min (4°C). The protein A Sepharose CL-4B was then washed five times by centrifugation (200 x g, 10 sec) in 0.5% NP-40 buffer and once in cold water (200 x g, 30 sec). Bound immune complexes were denatured by boiling for 5 min in sample buffer containing 80mM Tris (pH 6.8), 3.0% (w/v) sodium dodecyl sulfate (SDS), 15% sucrose, 0.001 bromphenyl blue and (5.0% v/v) β -mercaptoethanol. The Sepharose beads were removed by centrifugation (200 x g, 1 min) and the supernatant electrophoresed through SDS 12% polyacrylamide separating gels, followed by coomassie staining and autoradiography.

The initial studies were to learn whether 64KA occurred in NOD mice. Sera were obtained from 8 female NOD mice with newly diagnosed IDD (mean age at onset: 104.5 ± 13.5 days; range, 93 to 134 days) and 11 healthy control mice (2 male and 9 female, mean age : 97.7 ± 30.4 days, range 50 to 120 days) of the BALB/c (n=5), C57BL/6 (n=4), and C3H/HeJ (n=2) strains.

The 64KA was detected in 87% of NOD at the onset of their diabetes, but in none of the non-diabetes prone control strains ($P < 0.001$). The presence of the 64K autoantibody in a high percentage of NOD mice with newly diagnosed IDD in conjunction with the absence of 64KA in age-matched non diabetes prone control mice, argues that the 64KA is specific for IDD and its prodromal state. The presence of 64KA was also one of the initial events detectable, being generally present even at or before weaning at the very earliest age that insulinitis could be identified.

Example 4 – 64KA as a Predictor of IDD in NOD Mice

In order to learn about the natural history of 64K autoantibodies with respect to IDD, serum samples obtained from 5 mice at weaning (2 male and 3 female; age 23-25 days) were analyzed and their pancreases examined histologically for insulinitis. Insulinitis was defined as an unequivocal intra-islet infiltrate of lymphocytes on haematoxylin and eosin stained pancreatic sections containing 5 or more islets. The 64KA were already present in 80% (4/5) of these mice. Concomitantly, early insulinitis was also present in 3 of the 4 mice whose pancreatic histologies were analyzed. In contrast, 2 animals (both male) studied at ≥ 190 days of age who had never developed IDD, had no 64KA, albeit both had insulinitis.

Example 5 – 64KA in BB Rats

5 In studies of IDD seen in BB rats (n=8), autoantibodies to the 64K protein appear early in the natural history of the disease and show considerable specificity (absence in 6 Lewis rat controls) as markers for IDD. The finding of 64KA in humans, NOD mice, and BB rats suggests that autoimmunity may be of considerable pathogenic importance and that the 64K protein may have a vital physiological function in normal beta cells.

Example 6 – Biochemical Characterization of 64K Antigen

10 With respect to biochemical characterization, higher resolution of 64 K protein gels suggest that it may consist of a doublet (or triplet) differing by approximately 0.5 kilodalton between the two components (63,500 and 64,000 M_r). The 64K component migrates to the M_r 64,000 range under reduced conditions, and may be found as a dimer (approx. 130K) or trimer (approx. 15 190K) under non-reducing conditions. The 64 K protein displays charge heterogeneity in that it has an isoelectric point of 6.4 to 6.7. The 64K component most likely represents an integral islet cell membrane protein, due to its hydrophobic nature observed in immunoprecipitation of detergent phase extracts. As used in this patent application, the term "64K antigen" refers to the 20 compound, compounds, or complex which behaves on a gel in the manner described herein. As used in this application, "immunological equivalents of 64K antigen" refers to peptides which react with the 64KA. The terms "64KA or 64K autoantibody" refer to the compound or compounds which react with the 64K antigen.

25 Because the protein shows an amphiphilic nature, we performed experiments to observe if the 64K protein was essentially restricted to the cellular plasma membrane, and if so, was there also evidence for surface expression of this protein in normal islet cells.

Our biochemical characterization studies have shown no evidence for glycosylation of the 64K protein, a characteristic common to surface expressed proteins. A series of broad spectrum enzymes that would detect the common forms of protein carbohydrate glycosylation were used. This analysis used the enzymes N-GLYCANASE™ (for N-linked carbohydrates) treatment for O-linked carbohydrates, Neuraminidase (for sialic acid groups), and beta endogalactosidase (for galactose groups). If one of the carbohydrate groups was present on the 64K protein, the enzyme would cleave that carbohydrate, and upon subsequent SDS-page analysis the mobility of the 64K protein would increase, and show a protein of decreased molecular weight. There were no detectable differences in the mobility of the 64K protein in SDS-page gels after treatment of the protein with this particular series of enzymes. Thus, it appears that there is no glycosylation of the 64K protein.

Finally, it has been previously shown (Colman et al., [1987] Diabetes 36:1432-1440) using a standard technique of radioactively labeling cell surface proteins exclusively, that no 64K protein could be immunoprecipitated from surface labeled islet cells with sera from diabetic patients. It was proposed in that work that the evidence for surface expression was therefore absent. However, that common technique labeled tyrosines (a relatively rare amino acid that may not be present at the extracellular portion of the protein), and was stringent in nature. Thus, it could be stringent enough to destroy the antigenic binding site of the 64K protein so that the antibody could no longer bind to the protein. However, we used a newly described technique (Thompson, J. et al. [1987] Biochemistry 26:743-750)², that was much less stringent in chemical nature, one which radiolabeled lysines (an amino acid much more common than tyrosines), and one that was shown to label cell surface proteins with a much higher specific activity than the method used in the Colman et al. paper. Cell surface amino groups were derivatized with ¹²⁵I (hydroxyphenyl) propionyl groups

via ^{125}I sulfosuccinimidyl (hydroxyphenyl) propionate. However, even with these assay improvements, no 64K protein could be immunoprecipitated from intact cell surface labeled human islet cells.

5 In order to confirm that the 64K protein was indeed present within the plasma membrane, we made crude membrane preparations of islet cells, and using the reagent Triton X-114, immunoprecipitated the 64K protein using sera from patients with IDD. Next, we developed an improved method for the detection of autoantibodies to 64K protein. The method used no detergent, and as gives a result that is easier to interpret and more rapid. The method involves
10 making crude membrane preparations of ^{35}S methionine labeled islet cells, followed by trypsinization for 60 minutes at 4°C (2 mg/ml 50 mM Tris buffer, pH 7.4). The material is then centrifuged, followed by our standard immunoprecipitation technique. Following gel electrophoresis and autoradiography, a 40K band can be observed with immunoprecipitations from
15 diabetic sera and not in controls. As we have also shown that isolated 64K protein treated with trypsin also reveals a 40K protein, this 40K band that is immunoprecipitated directly from trypsin treated islets most likely represents the same protein. Not only is the assay for the 40K protein an improvement for simpler detection of 64K autoantibodies, it also yields a product that is much
20 more amenable to gas phase sequence analysis using imobilon membrane. The reason for this improvement is that the 40K fragment is most likely devoid of a major hydrophobic region that has caused difficulties in our determination of N-terminal amino acid sequence of 64K protein bound to IMMOBILONTM using the Applied Biosystems gas phase sequencer. It has been established that
25 proteins with strong hydrophobic regions solubilize with solvents used in the gas phase sequencer, and therefore represent a major technical hurdle to direct sequencing of this protein. It is also much easier to visualize the 40K protein

than the 64K protein in silver staining of the SDS page gels; due to lower background staining in the 40,000 Mr range than in the 64,000 Mr range.

Example 7

5 Many key regulatory proteins exist in cells as either a phosphorylated or dephosphorylated form, their steady-state levels of phosphorylation reflect the relative activities of the protein kinases and protein phosphatases that catalyze the interconversion process. Phosphorylation of serine, threonine, or occasionally
10 tyrosine residues triggers a small conformational change in these proteins that alter their biochemical properties and biological properties. Hormones and other extracellular signals transmit information to the interior of the cell by activating transmembrane signalling systems that control the production of a relatively small number of chemical mediators termed "second messengers". These substances
15 in turn regulate the activities of protein kinases and phosphatases, and so alter the phosphorylation states of many intracellular proteins.

 Although the full extent of the protein kinases within the human islet remains to be identified, we have applied the in vitro kinase assay using sera and islet cell proteins as an approach to identify any protein kinases which many have a role in the autoimmune destruction that results in IDD.

20 Two groups of individuals were selected for the in vitro kinase assay studies. There were 7 new onset IDD patients diagnosed according to the established National Diabetes Data Group (NDDG) criteria (National Diabetes Data Group. Diabetes. 1979; 28:1039-57), that had been referred to the University of Florida, Diabetes Clinics. We also studied 8 non-diabetic controls
25 without any known family history of autoimmune disease. Human pancreatic islets isolated from cadaveric pancreases, were of $91.2 \pm 2.3\%$ purity, and had insulin content of 0.4 ± 0.1 mU insulin per islet. Following 48 hours of in vitro culture including the exclusive use of normal human serum, the islet cells were

immunoprecipitated as follows: Immune complexes were prepared with sera from either patients with IDD or controls that were incubated with islet cell detergent extracts, followed by incubation with gamma ^{32}P -ATP, and the products phosphorylated in vitro were analyzed on SDS-PAGE gels. Islet cells (1000/test sera) were lysed (3 h, 4°C) in 50mM Tris buffer (2% Triton X-114, Aprotinin, PMSF, NaF). The detergent lysates were incubated with normal human serum (100 μl /1000 islets), followed by adsorption to an excess of protein A Sepharose CL-4B (Pharmacia). Aliquots containing unbound (pre-cleared) lysate were incubated with either IDD or control sera (25 μl , 18 h, 4°C). Following incubation of the immunoglobulins with the protein A Sepharose CL-4B (2 h, 4°C), the complexes were then washed 3 times with 50 mM Tris-HCl (pH 7.4) with 0.1% SDS, 1.0% Triton X-114, and 2 mM EDTA, and two times with 50mM Tris-HCl (pH 7.4). Kinase reactions were initiated by adding 10 μl of 50mM HEPES buffer (pH 7.4) containing 10 mM MnCl_2 , 10 mM MgCl_2 , 1% Triton X-114, and 20 μCi of adenosine (gamma- ^{32}P) 5' triphosphate (Amersham, >5000 Ci/mmol). The precipitates were suspended and incubated for 10 minutes at 30°. Reactions were terminated by the addition of electrophoresis sample buffer and heated to 95°C for 4 minutes. The ^{32}P labeled products were separated by discontinuous SDS 15% polyacrylamide separating gels, followed by autoradiography from 6 to 72 hours with intensifying screens (Kodak, X-omat AR5). The IDD patients sera specifically immunoprecipitated an M_r 64,000 protein, which was not observed with the control sera.

More than 65 protein kinases have been identified to date (Hanks et al. [1988] Science 241:42-52), and can be classified according to the amino acid(s) phosphorylated. Identification of phosphorylated serine, threonine, and tyrosine residues can be accomplished by isolation and analysis of the ^{32}P labeled protein from SDS-PAGE gels. IMMOBILON™, a membrane of polyvinylidene difluoride to which SDS-PAGE fractionated proteins can be transferred

electrophoretically, was used as a matrix for the analysis of the phosphoamino acid content of the phosphoproteins. ^{32}P labeled M_r 64,000 protein bound to IMMOBILONTM was acid hydrolysed and the released phosphoamino acids and phosphopeptides were analysed by two-dimensional electrophoresis. The membranes were either subjected to autoradiography directly, or to base hydrolysis (1.0 N HCl, 2 h, 55°C) prior to autoradiography. Following alignment of the autoradiograph with the imobilon membrane, the M_r 64,000 containing protein was isolated (cut) from the IMMOBILONTM membrane, and subjected to acid hydrolysis (5.7 N HCl, 1 h, 110°C). The hydrolysis products were analyzed by two-dimensional paper electrophoresis after suspension in buffer containing authentic phosphotyrosine (Y), phosphoserine (S), and phosphothreonine (T) standards. Separation was performed for 4 hours at 900 volts from left (cathode) to right (anode) in acetic acid-formic acid-water (15:5:80, pH 1.9). The paper was then rotated 90° for electrophoresis in the second dimension from the bottom (cathode) to top (anode) in acetic acid-pyridine-water (5:0.5:94.5, pH 3.5) for 1.5 hours at 900 volts. The dried paper was analyzed by a BETAGENTTM analyzer, and the radioactive spots were aligned with the phosphoamino acid standards visualized by ninhydrin staining (Cooper, J. et al. [1983] *Methods Enzymol.* 99:387-402). Using this technique, we identified the 64,000 M_r protein to have serine phosphorylation specificity; hence, a serine kinase. Because the detection of ^{32}P labeled phosphotyrosine containing proteins have been shown (Kamps, M. et al. [1989] *Analytical Biochem.* 176:22-27) to be substantially improved by incubation of the IMMOBILONTM with base prior to acid hydrolysis, parallel 2-dimensional phosphoamino acid studies using this technique were also performed. However, the base hydrolysis technique removed the ^{32}P signal observed in phosphoamino acid analysis of the M_r 64,000 protein. This observation is again indicative of a serine-kinase specificity, and not a tyrosine specificity.

Further experimentation was performed in order to confirm the serine amino acid specificity for the phosphorylation reaction. Because of the availability of phosphotyrosine specific antisera (Boehringer Mannheim, 1G2), western blots were performed (Towbin, H. et al. [1979] Proc. Natl. Acad. Sci. USA 76(9):4350-4354) using M_r 64,000 protein transferred from SDS-Page gels to IMMOBILON™ membranes. Although a positive reaction was observed between the anti-phosphotyrosine antisera and a positive control phosphotyrosine, no reaction was observed between the M_r 64,000 protein and the anti-phosphotyrosine antibody.

Finally, in order to analyze if the identity of the M_r 64,000 protein detected by the in vitro kinase reaction was identical to that observed with immunoprecipitates of metabolically labeled islet cells, tryptic peptide mapping experiments were performed. Treatment of the ^{35}S methionine labeled islet cell M_r 64,000 protein immunoprecipitated with IDD sera showed a similar tryptic peptide mapping as that of the in vitro phosphorylated M_r 64,000 protein.

Specifically, the 64,000 M_r and 125,000 M_r proteins were excised from SDS-PAGE gels, and the proteins were treated with 1 mg/ml of trypsin (3-30 minutes, 4°C). The resulting proteins were re-run on SDS-PAGE gels. The 125,000 M_r protein was not affected by this treatment. However, the 64,000 M_r protein increased in mobility to the 40,000 M_r range. Thus, this 64,000 ^{32}P labeled islet cell serine kinase shows the same M_r (40,000) when treated with trypsin, as we have observed with the M_r 64,000 ^{35}S methionine labeled islet cell protein.

The knowledge that the 64K protein is a member of the serine kinase system will have major implications in the designing of kits for the detection of autoantibodies to the 64K protein, and the determination of autoantibody binding sites on the protein. We have established that the 64K protein is restricted to the insulin producing pancreatic beta cells. However, the serine kinase class of proteins is not restricted to these beta cells, but does represent a evolutionarily conserved group of proteins that perform similar functions throughout the body.

In the case of the pancreatic beta cell, there must exist a tissue (cell) specific form of the 64K serine kinase protein, since when we use 64K autoantibody positive sera we cannot detect a 64K protein on other endocrine or non-endocrine tissues. From this information, a number of points can be made.

5 First, since to our knowledge IDD only involve the specific destruction of pancreatic beta cells, the 64K protein must have some unique sequence characteristics that place it apart from other cellular serine kinases. If this were not the case, the autoantibodies would cross react with multiple serine kinases, and possibly multiple cell types could be affected by autoimmunity to the 64K-
10 like serine kinases. In the design of any kits for the detection of 64K autoantibodies, careful construction will have to be made to identify all the possible regions of the 64K protein that the autoantibodies may bind to (using parameters such as 3 dimensional modeling, hydrophilicity, folding, etc.), however the sequences must be specific enough so that the autoantibodies do not cross
15 react with any other serine kinases.

Second, we would assume that the autoantibody binding region to the 64K protein would involve all or part of these unique regions. Third, because these serine kinases represent a normal cellular class of proteins, there is also the possibility that IDD may result from either the overexpression or alternate
20 presentation of this serine kinase in the islet beta cell of persons destined to develop the disease. If this were so, therapies that would alter the regulation or immunogenicity of this serine kinase should be considered.

Example 8 – Collection of Biological Fluid for Detection of 64K Autoantibodies

25 A volume of greater than 500 microliters of whole blood is collected from the individual to be tested for 64KA autoantibodies. The blood is drawn into a glass vacutainer tube directly, or into a syringe followed by transfer into a glass vacutainer tube. In order to obtain sera (blood devoid of clotting factors), the

common vacutainer tubes used are termed a red top tube (devoid of sodium heparin), or a serum separator (STS) tube. If a common red top tube is used, the tube is allowed to clot (a period of greater than 10 minutes), and the clot removed. At this period of time, either sample tube may be centrifuged for 5 minutes at 1000 rpm at room temperature. The serum within the sample is removed and placed into a plastic storage vial and sealed tightly. The sample can be frozen at -20° until 64K autoantibody analysis.

Example 9 – Preparation of 64K Antigen for Use in Testing Biological Fluids

Before a sample can be tested for 64K autoantibodies, human islet cell preparations must be isolated and metabolically labeled to provide a source of 64K antigen. Human islet cell preparations can be isolated from cadaveric human pancreatic donors as outlined in detail according to the method of Ricordi et al. (Ricordi, C., Lacy, P.E., Finke, E.H., Olack, B.J., and Scharp, D.W. [1988] "Automated method for isolation of human pancreatic islets," Diabetes 37:413-420). Islet cells can be stored in T-150 plastic tissue culture flasks at a concentration of 6,000 islets/T-150 flask in 50 milliliters of CMRL media.

Before testing, the CMRL media is removed and discarded. To each flask, 50 milliliters of RPMI 1640 media (supplemented with 16 mM glucose, 100 μ U/milliliter Penicillin, 100 μ G/milliliter Streptomycin, and 2% v/v normal human serum) are added to each flask, and allowed to incubate overnight in culture at 37°C in an atmosphere of 95% air/5% CO_2 . The islets are collected into centrifuge tubes at a concentration of 50 milliliters of media per tube.

The tubes are capped and centrifuged for 3 minutes at 1000 rpm at room temperature. The supernatant is removed and discarded. A small amount (approximately 4 milliliters) of RPMI labeling media (supplemented with 16mM glucose, 20 mM HEPES, 2% normal human serum, and free of the amino acid methionine) is added to each tube with gentle mixing for approximately 30

seconds per tube. All islet cells are then collected into one 50 milliliter polypropylene centrifuge tube and centrifuged at 1000 rpm for 5 minutes. The supernatant is removed and discarded. The islet cells are then resuspended in RPMI labeling media (1000 islet/milliliter media), and transferred to a 100 mm plastic tissue culture petri dish. The islets are incubated for 15 minutes at 37°C (95% air/5% CO₂), after which time ³⁵S methionine is added to the media at a concentration of 0.5 mCi/1 x 10⁴ cells. The islet cells are once again incubated for 5 hours at 37°C (95% air/5% CO₂). The media within the petri dishes is aspirated without disrupting (or collecting) the islet cells, and the media disposed of.

To the cells is then added an equivalent volume of RPMI 1640 media at a concentration of 1000 islets/ml and incubation at 37°C (95%air/5%CO₂) for 30 minutes. The islet cells and their media are collected into 15 ml conical polypropylene centrifuge tubes. The tubes are filled to the 15 ml marking with buffer containing 20mM Tris (pH 7.4), 150mM NaCl, 1000 KIE/ml aprotinin and 2mM phenylmethyl sulfonyl fluoride, capped, centrifuged (1000 rpm, 5 minutes), and the supernatant discarded. The tube containing the pellet can then be frozen (-80°C).

Example 10 – Detergent Extraction of 64K Antigen and Testing of Biological Fluid for 64K Autoantibodies

In order to perform immunoprecipitation of the 64K antigen using test sera, the islet cells are slowly thawed in their tube on ice. Once thawed, a detergent extraction buffer (20mM Tris (pH 7.4), 150mM NaCl, 1000 KIE/ml aprotinin and 2mM phenylmethyl sulfonyl fluoride, and 2% TRITON™X-114) is added to the tube, and the islets lysed for 3 hours on ice. In addition, the islets are sonicated within their tube for a total of 60 seconds (4 times at 15

second intervals with 1 minute rests on ice between each sonication) using a sonication probe inserted into the detergent extract. At 15 minute intervals, the islets are also mechanically disrupted.

5 The insoluble material is removed from the detergent extracted islets by pipetting equal volumes of the extract into centrifuge tubes, placing the balanced tubes into a Beckman type 50 rotor, and ultracentrifuging the tubes (100,000 x g, 30 minutes, 4°C). The supernatant is removed and placed into a new polypropylene tube. The pellet may be discarded. The islet cell lysate (supernatant) can then be separated into aqueous, sucrose, and detergent phases
10 prior to immunoprecipitation studies.

The method for detergent phase extraction is followed directly from the methodology of Bordier (Bordier, C. [1981] "Phase separation of integral membrane proteins in TRITON™X-114 solutions," J. Biol. Chem. 256:1604-07).

15 After extraction, the detergent phase of the islet cell lysate is then incubated in a capped 1.5 ml epindorf tube with normal human serum (10 µl of test sera per 100 µl of detergent phase supernatant, 1 hour, 4°C [ice bath]), followed by adsorption to pre-swollen protein A Sepharose CL-4B (can be purchased from Pharmacia, Sweden). One-hundred µl of swollen protein A sepharose CL-4B is added to each 400 µl of test sera/detergent phase mix in a
20 capped 15ml conical centrifuge tube, and maintained at 4°C, on a shaking platform @ 300 rpm for 2 hours). At that time, the tube can be centrifuged for 1 minute at 1000 rpm, and the supernatant removed. The protein A sepharose pellet can be discarded. Aliquots (100 µl containing 5-10 x 10⁶ cpm) of unbound (pre-cleared) lysate (supernatant) is distributed into 1.5 ml epindorf centrifuge
25 tube and incubated with 25 µl of the sera which is to be tested for the presence of 64K autoantibodies. The tubes are then capped and incubated at 4°C (ice bath) for 18 hours.

To each assay tube, 100 μ l of pre-swollen protein A Sepharose CL-4B is added, and the reaction mixture is incubated for 2 hours at 4°C on a shaking platform @ 300 rpm. To the tubes is added 900 μ l of 0.5% TRITON™X-114 buffer in order to wash the protein A Sepharose CL-4B. The tubes are vortexed for 10 seconds each, followed by centrifugation for 10 seconds at 1000 rpm. The supernatant is discarded by aspiration, and the pellet left remaining in the tube. Another 900 μ l of 0.5% TRITON™ wash buffer is added to the tube, and the wash procedure repeated 5 more times. One final wash step occurs with the exception that ice cold water wash is substituted for the 0.5% TRITON™ buffer.

At this point, the tubes should only contain a pellet composed of protein A Sepharose CL-4B and any immune complexes formed between antibodies and/or islet proteins. The bound immune complexes can be removed and denatured by boiling for 3 minutes in 100 μ l of sample buffer containing 80mM Tris (pH 6.8), 3.0% (w/v) sodium dodecyl sulfate (SDS), 15% sucrose, 0.001 bromphenyl blue and (5.0% v/v) β -mercaptoethanol in the same capped 1.5 ml epindorf tube. The Sepharose beads are then removed by centrifugation of the tubes (1000 rpm, 1 minute) and the supernatant carefully removed. Fifty μ l of the sample is then electrophoresed through discontinuous SDS 10% polyacrylamide separating gels followed by Coomassie Brilliant Blue staining, according to the method of Laemmli [Laemmli, U.K. 1970. Cleavage of structural proteins during the assembly of the head of bacteriophage T4. Nature, 227:680-85], followed by fluorography using the methods detailed in the commercial product Enhance (New England Nuclear).

Following electrophoresis, the gels are placed on filter paper, and dried for 2 hours at 60°C in a electrophoresis gel dryer. Once dry, the gels are removed and placed on X ray film (Kodak XR OMAT) in film cassettes with intensifying screens, and placed for 3 weeks at -80°C. The films (termed fluororadiographs) are processed using standard X ray film photo processing. Test samples are

rated as positive or negative after comparison with their respective positive and negative controls.

Example 11 – Methods of Detecting 64KA

5 In addition to the use of immunoprecipitation techniques outlined in Example 9, the subject invention can be practiced utilizing any procedures which facilitate detecting the presence of 64KA. For example, other immunological methods which can be used include enzyme linked immunosorbent assay (ELISA) and radioimmunoassay (RIA). The principles and experimental methods of these
10 procedures are well known to those skilled in the art. The assays can be carried out rapidly and efficiently by the use of natural or recombinant proteins which bind with the 64KA. Both whole cell and cell lysate procedures are familiar to those working in this field and can be readily employed to detect the 64KA of the subject invention.

15 Also, an alternative to using 64K antigen to detect 64KA would be to use anti-64KA antibody. This antibody would immunoprecipitate with 64KA, and the detection could be carried out as described above.

Example 12 – Assay for Detecting 64K Autoantigen-Autoantibody in Immune Complexes

20 Patients who have IDD or who are in the process of developing the disease can be expected to have, within their blood sera, immune complexes which comprise the 64K autoantigen. These immune complexes typically consist of the 64K autoantigen surrounded by several immunoglobulins. Because individuals
25 who do not have the disease, or who are not developing it, would not have these immune complexes, the detection of these complexes provides the basis for an assay for detecting this disease.

Initially, blood is drawn from patients to be tested for IDD or from controls. Sera can be obtained by spinning out the red blood cells from the blood sample. For patients with IDD, or those who are developing the disease, this sera can be expected to contain the immune complexes which comprise the 64K autoantigen. Next, a sample of the sera can be incubated with protein A Sepharose. The volume of sample incubated with the sera may be, for example, 25 μ l. Following incubation of the immunoglobulins with protein A Sepharose CL-4B (2 hours, 4°C), the complexes can be then washed 3 times with 50 mM Tris-HCl (pH 7.4) with 0.1% SDS, 1.0% Triton X-114, and 2 mM EDTA, and two times with 50mM Tris-HCl (pH 7.4). By washing the sepharose as described, extraneous sera protein are washed away, leaving only immunoglobulins which have bound to the protein A Sepharose. The radioactive phosphorylation of the 64K autoantigen can then be accomplished utilizing a kinase reaction. Kinase reactions can be initiated by adding 10 μ l of 50mM HEPES buffer (pH 7.4) containing 10 mM $MnCl_2$, 10 mM $MgCl_2$, 1% Triton X-114, and 20 μ Ci of adenosine (gamma- ^{32}P) 5' triphosphate (Amersham, >5000 Ci/mmol). The precipitates can be suspended and incubated for 10 minutes at 30°. Reactions can then be terminated by the addition of electrophoresis sample buffer and heated to 95°C for 4 minutes. The ^{32}P labeled products can be separated by discontinuous SDS 15% polyacrylamide separating gels, followed by autoradiography from 6 to 72 hours with intensifying screens (Kodak, X-omat AR5). The IDD patients sera specifically immunoprecipitate an M_r 64,000 protein, which is not observed with the control sera.

Example 13 – Treatment of IDD using Hybrid Proteins

The specific event or agent which triggers the onset of diabetes has not been identified. A virus carrying an antigen similar to the 64K antigen may invade beta cells and provoke both a normal immune response to the virus and

also an abnormal, autoimmune response to the 64K antigen. Alternatively, genetic susceptibility in association with an unknown environmental agent may initiate the disease. It is also possible that the 64K protein may have a delayed expression in the development of islet cells, rendering it antigenic. The 64K protein may also be homologous to lymphocyte serine kinase genes, or oncogens, which renders it antigenic in the context of the islet cell.

Regardless of the mechanism of disease initiation, beta cell destruction could proceed in at least two ways. 64KA could bind to the initiating exogenous antigen and stimulate other parts of the immune system to destroy the bound beta cells. Or, T-lymphocytes could recognize the antigen and destroy the cells directly. In either case it is possible, using the 64K protein, to interfere with the destructive process, thereby delaying or preventing IDD.

The novel therapy of the subject invention involves the injection into the bloodstream of a toxin bound to a purified form of the 64K antigen. The antigen-toxin complex would quickly reach the lymph nodes where it is taken up by immune cells that normally produce the 64KA. Also, the antigen-toxin complex would be bound by the T-lymphocytes that recognize the 64K antigens on beta cells. Thus, the specific immune cells involved in beta cell destruction are poisoned and inactivated, leaving non-destructive immune cells unharmed.

The hybrid protein could comprise, for example, a diphtheria toxin joined together with the 64K antigen. The construction of such a hybrid toxin could proceed, for example, according to the disclosure of United States Patent Number 4,675,382 (Murphy) relating to hybrid proteins.

Example 14 – Use of 64KA in Conjunction with Pancreas Transplantation

A preferred approach for treatment of a patient with IDD would be to transplant normal islets as replacements for the damaged or destroyed beta cells. Segmental and whole pancreas transplantations have been performed successfully

in a number of patients with diabetes. However, permanent immunosuppressive therapy is always required to maintain the grafts and prevent rejection. Segmental or whole pancreas transplants under continuous immunosuppressive therapy have produced normal levels of blood glucose in some patients with diabetes. Pancreatic transplants are done late in the course of diabetes and will probably not reverse complications such as nephropathy and indeed may worsen retinopathy.

Importantly, successful pancreatic grafts between identical twins have been maintained without immunosuppressors; however, autoimmune islet cell destruction has occurred with recurrence of diabetes. Thus, even when the graft is not rejected, there is obligatory need for immunotherapies to prevent disease recurrence. The destruction (rejection) of transplanted islets may be due, at least in part, to the re-presentation of autoantigens responsible for the autoimmune destruction. There is no specific immunotherapy to prevent the autoimmune destruction (rejection of transplanted islets/pancreas) at present. In order to prevent the autoimmune destruction of either transplanted islet cells or pancreas, a specific immunotherapy using a hybrid toxin, as detailed in Example 11, can be used to prevent islet cell destruction. The combined use of the immunotherapies could make islet cell/pancreas transplantation a therapeutic tool for the treatment of IDD.

Example 15 – Kits for Assay of 64KA

A reagent kit can be provided which facilitates convenient analysis of serum samples using the novel procedures described here. Kits can be prepared which utilize recombinant or synthetically produced intact 64K protein(s) or immunoreactive peptides to serve as an antigen for the detection of 64KA. Alternatively, antibodies specifically developed to detect 64KA may also be

useful. The principles and methods for ELISA and RIA technologies to detect antibodies are well-established.

As an example, for the ELISA assay, one such kit could comprise the following components:

- 5 1. 64K protein, peptide, or anti-64KA antibody;
2. Enzyme (e.g., peroxidase);
3. Conjugated animal anti-human immunoglobulin; and
4. Positive and negative controls.

10 The above kit could be modified to include 96 well plastic plates, colorimetric reagents, ELISA readers, blocking reagents, and wash buffers.

Also by way of example, for the RIA, one such kit could comprise the following components:

1. Radiolabeled 64K protein(s), peptide, or anti-64KA antibody;
2. Wash buffers;
- 15 3. Polyethylene glycol;
4. Goat or sheep antihuman precipitating (second) antibodies; and
5. Positive and negative controls.

20 Either of the above kits may be modified to include any appropriate laboratory supplies.

Example 16 – Construction of Human Islet cDNA Library

25 A cDNA library for human islet cells has been constructed in the lambda gt11 vector (Young, R.A., and Davis, R.W. [1983] Proc. Natl. Acad. Sci. USA 80:1194-1198). Messenger RNA was isolated and purified from approximately 200,000 purified human islets according to a modification of the method of Chirgwin et al (Chirgwin, J.M., A.E. Przybyla, R.J. MacDonald, and W.J. Rutter [1979] Biochemistry 18:5294-5299). The islets were lysed in 4M guanidine

thiocyanate containing 1M 2-mercaptoethanol and 0.1M Tris-HCl (pH 7.4). The lysate was layered over a 5.7M cushion of CsCl and subjected to centrifugation at 37,000rpm in a Beckman SW50.1 rotor for 17 hours. The RNA pellet was removed and resuspended in sterile water followed by precipitation with three volumes of absolute ethanol. This final step was repeated three times to insure a clean preparation of RNA. The cDNA for the library was synthesized using human islet total RNA as template and the enzyme reverse transcriptase in the presence of human placental ribonuclease inhibitor, oligo(dT) primer, and the four deoxyribonucleotide triphosphates. The mixture was incubated at 40°C for 2 hours. The second strand of the cDNA was synthesized using the products of the first strand reaction and the enzymes *E. coli* DNA polymerase I and *E. coli* ribonuclease H. The mixture was incubated sequentially at 12°C for 60 min then 22°C for 60 min followed by heat inactivation at 65°C for 10 min. To insure that the ends of the cDNA were flush, the mixture was incubated with T4 DNA polymerase for 10 min at 37°C. This mixture of double-stranded cDNA (ds-cDNA) was then purified using extraction with an equal volume of buffer saturated phenol/chloroform, followed by an extraction with an equal volume of chloroform. The unincorporated nucleotides were removed by the addition of an equal volume of 4M ammonium acetate followed by the addition of two volumes of absolute ethanol. After chilling for 15 min on dry ice, the mixture was centrifuged for 10 min at 12,000 rpm in a microcentrifuge. This precipitation step was repeated two times to insure the complete removal of the unincorporated nucleotides.

The ds-cDNA was prepared for cloning into the vector by a series of modification steps, beginning with an incubation with the enzyme *EcoRI* methylase in the presence of S-adenosyl-methionine for 1 hour at 37°C. This methylated cDNA was ligated to synthetic *EcoRI* linkers in the presence of T4 DNA ligase and ATP overnight at 15°C. Cohesive *EcoRI* ends were generated

on the linked cDNA by digestion with EcoRI endonuclease for 5 hours at 37°C. Following this step, the excess linkers were removed from the mixture by column chromatography. The material that eluted in the void volume of this column represented the ds-cDNA that had been methylated, ligated to EcoRI linkers, and size-selected.

This material was ligated to lambda gt11 vector that had been digested with EcoRI and treated with alkaline phosphatase. The ligation proceeded in the presence of T4 DNA ligase and ATP overnight at 15°C. Each ligation mixture was packaged into phage lambda coat proteins using a commercially available extract (Stratagene). The levels of packaged phage were determined by titration on the E. coli host strain, Y1088. The size of the library was determined to be approximately 6.0×10^6 pfu, of which 81% contained inserted cDNA as detected by the absence of color on bromo-chloro-indolyl-galactoside (BCIG) indicator.

The recombinant library was amplified prior to screening. This was accomplished by plating the phage on E. coli strain Y1088 at a density of approximately 1×10^5 pfu/plate (150mm petri plates). The plates were incubated for 8 hours at 37°C to allow a low level of growth without achieving confluence. The plates were then flooded with 12 mls of SM buffer (0.1M NaCl, 50mM Tris-HCl (pH7.4), 10mM MgCl₂, and 0.01% gelatin), and incubated overnight at 4°C with gentle shaking. The buffer containing the phage was aspirated from the plates and treated with DNase I and RNase A for 30 min at 37°C. Following a centrifugation at $10,000 \times g$ for 10 min, the supernatant was made 1M in NaCl and 10% in polyethylene glycol (PEG). This mixture was incubated overnight at 4°C and then centrifuged at $10,000 \times g$ for 20 min. The pellet was resuspended in SM buffer and 0.77g CsCl was added per ml of phage suspension. This mixture was subjected to centrifugation overnight at 45,000 rpm in a Beckman VTi50 rotor. The phage band was removed from the CsCl gradient and stored at 4°C with a titer of 0.5×10^{13} pfu/ml.

Example 17 – Identification of the 64,000 M_r Islet Cell Serine Kinase Gene

Because of our identification of the 64,000 M_r autoantigen as a serine kinase, we will use highly conserved oligonucleotide probes that have been shown to be effective in identifying serine kinase genes (Hanks, S. [1987] Proc. Natl. Acad. Sci. 84:388-392) to identify the gene from interest from our islet cell cDNA library. The following probes will be used:

Probe 1

3' CTGA_AGT_CTT_CTGGNCTT_CTT 5'

Probe 2

3' CCGTGGGG_AGCTCAT_AGGA_CGCGGG_AGNCT_T5'

Two different approaches will be undertaken.

The first approach makes use of the advantages afforded by the polymerase chain reaction (PCR) technique. Using two highly conserved probes (otherwise known as primers) for a family of genes (Wilkes, A. et al. Proc. Natl. Acad. Sci. 86:1603-1607) has shown the ability of the PCR technique to amplify the kinase genes from a liver cell cDNA library. Thus, the aforementioned probes can be used as primers to amplify all of the serine kinase genes present within the human islet cell cDNA library. All PCR amplified products can be subcloned into the M₁₃mp18 vector for sequencing, and the products can be assigned as to their type (function) of serine kinase based upon the cDNA sequence amplified between the two primers. In other words, although the

regions that the primers (probes) bind to is highly conserved, the sequence of amplified products between these two can be diverse enough to identify the protein which a particular cDNA amplified product represents. Specific probes corresponding to these amplified regions can be designed to identify only one gene of interest. This newly designed probe can then be ^{32}P -labeled, and using the technique of oligonucleotide probing (Example 18), the entire gene can be identified.

The second approach is more basic in that the oligonucleotide probe will be used in hybridization studies (Example 18) using the human islet cell cDNA library. All positive clones will be re-screened with Probe 2. Those cDNA clones hybridizing to both probes will represent those encoding serine kinase genes. Those clones can then be sequenced (Example 18) and the DNA/protein sequence of the 64,000 M_r autoantigen determined.

Example 18 – Screening Human Islet cDNA Library for Serine Protein Kinase Sequences

For the purpose of screening the library, oligonucleotide probes can be radiolabeled at the 5' end using the enzyme T4 polynucleotide kinase in the presence of ^{32}P -ATP. A portion of the cDNA library can be plated at a density of approximately 4,000 pfu/plate (100mm petri plates) on *E. coli* strain Y1088. Plates can be grown overnight at 37°C followed by transfer of the plaque pattern to nitrocellulose filters. The phage bound to the filters can be denatured and neutralized using the technique of Benton and Davis (1975) and baked at 80°C for 2 hours under vacuum. The filters can be pre-hybridized for 3 hours at 42°C in buffer containing 5x Denhardts solution (1X Denhardts = 0.02% bovine serum albumin, 0.02% ficoll, and 0.02% polyvinyl pyrrolidone), 5X SSC (1X SSC = 0.15M NaCl and 0.015M sodium citrate), 0.5% SDS, and 0.01M EDTA. The hybridization can be continued overnight in the same buffer containing 1mg/ml

denatured, sheared, salmon sperm DNA and 5×10^6 cpm/ml of the radioactive oligonucleotide at 42°C. Following the hybridization, unbound radioactivity can be washed away using 1x SSC at 42°C. Positive plaques, visualized by autoradiography, can be re-screened a total of three times during plaque purification.

Example 19 – Characterization of the Positive Clones

The size of the inserts of the positive clones can be determined by digestion with EcoRI followed by agarose gel electrophoresis.

For DNA sequence determination, the inserts of the positive clones can be subcloned into the single-stranded phage vector, M13mp18. This was accomplished by EcoRI digestion of 1 µg of DNA from both phages as well as the vector DNA. Following heat inactivation of the digestion, 200 µg of EcoRI-cut phage DNA can be mixed with 100 µg of EcoRI-cut M13mp18 DNA and incubated with T4 DNA ligase overnight at 12°C. E. coli JM105 can be made competent by treating exponentially growing cells with 0.05M CaCl₂ for 1 hour followed by heat shock in the presence of the ligated DNA for 5 min at 37°C. The mixture can be grown overnight on M9 plates and plaques with inserts were identified by the presence of colorless plaques when grown on BCIG indicator.

The plaques that contained inserted DNA sequences can be grown further and single-stranded M13 DNA prepared for them. The nucleotide sequence of the inserted DNA can then be determined using the dideoxynucleotide chain terminator method where a synthetic oligonucleotide serves as a primer for second strand DNA synthesis by a DNA polymerase (i.e., DNA polymerase I—Klenow fragment, or T7 DNA polymerase [SEQUENASE™]).

It should be understood that the examples and embodiments described herein are for illustrative purposes only and that various modifications or changes

in light thereof will be suggested to persons skilled in the art and are to be included within the spirit and purview of this application and the scope of the appended claims.

Claims

1 1. A process for determining if the onset of insulin dependent diabetes has
2 occurred in a human or other animal, said process comprising determining
3 whether 64K autoantibodies are present in a sample of biological fluid from the
4 human or animal suspected of having insulin dependent diabetes.

1 2. A process for detecting insulin dependent diabetes before the
2 observation of clinical symptoms, said process comprising the detection of 64K
3 autoantibodies, or immunologic equivalents thereof, in a sample of biological fluid
4 from a human or animal suspected of having insulin dependent diabetes.

1 3. A process for detecting the onset of insulin dependent diabetes, said
2 process comprising the analysis of a sample of biological fluid from a human or
3 animal suspected of having IDD for the presence of 64KA or an immunologic
4 equivalent thereof, the presence of said 64KA or equivalent indicating that the
5 onset of IDD has occurred.

1 4. A process, according to claim 1, wherein said biological fluid is a human
2 serum sample.

1 5. A process, according to claim 1, wherein the presence of 64KA is
2 detected using immunoprecipitation procedures.

1 6. A process, according to claim 1, wherein said biological fluid is
2 contacted with 64K antigen, or an immunological equivalent thereof, or a cell
3 which expresses either the 64K antigen or an immunological equivalent thereof.

1 7. A process, according to claim 6, wherein said contacting between the
2 biological fluid and the 64K antigen is done under conditions which permit
3 specific antigen/antibody immunocomplex formation between the 64K antigens
4 and antibodies present in the sample, and the formation of any such
5 immunocomplex is detected by means of a label.

1 8. A method for early detection of insulin dependent diabetes comprising
2 the steps of:

- 3 a) contacting a protein with a biological sample wherein said protein
4 specifically binds with 64KA to form an immunoprecipitate
5 comprising said protein bound to said 64KA;
6 b) contacting said protein with said sample under appropriate conditions
7 to allow said protein to bind to any of said 64KA present in said
8 sample to form said precipitate; and
9 c) detecting insulin dependent diabetes by determining whether any of
10 said immunoprecipitate is formed.

1 9. A method, according to claim 8, wherein said protein is an anti-64KA
2 antibody.

1 10. A method, according to claim 8, wherein said immunoprecipitate is
2 separated from said sample by gel electrophoresis.

1 11. A process for detecting, in a sample of biological fluid, evidence of
2 insulin dependent diabetes, said process comprising contacting said biological fluid
3 with 64K antigens, or immunologic equivalents thereof, under conditions which
4 permit formation of antigen/antibody immunocomplexes, and detecting, through
5 means of a label, the formation of said antigen/antibody immunocomplex.

1 12. A method for detecting the presence of 64KA in a biological fluid, said
2 method comprising the performance of whole cell or cell lysate ELISA on said
3 biological fluid, said ELISA is performed using recombinant microorganisms
4 which express proteins capable of specifically binding with 64KA.

1 13. A method of detecting the presence of 64KA in a sample of biological
2 fluid, said method comprising the steps of:
3 a) contacting said sample with a recombinant cell where said cell
4 expresses a protein which specifically binds with 64KA;
5 b) contacting said sample with said cell under conditions which permit
6 specific said protein to specifically bind with said 64KA present in the
7 sample; and
8 c) detecting such immunocomplex formation by means of a label to
9 thereby detect insulin dependent diabetes.

1 14. A process, according to claim 1, wherein said process further
2 comprises analyzing said biological fluid for the presence of ICA and/or IAA.

1 15. A composition used in the early detection of insulin dependent
2 diabetes, said composition comprising 64K antigen, or an immunologic equivalent,
3 capable of reacting with 64KA.

1 16. A composition, according to claim 15, wherein said immunologic
2 equivalent of 64K antigen is anti-64KA antibody.

1 17. A hybrid protein comprising 64K antigen, or an immunologic equivalent
2 thereof, together with a toxin.

1 18. A hybrid protein, according to claim 17, wherein said toxin is a
2 diphtheria toxin.

1 19. A method for treating a person with insulin dependent diabetes, said
2 method comprising the administration of an effective amount of a hybrid protein
3 comprising 64K antigen, or an immunologic equivalent thereof, together with a
4 toxin.

1 20. A method, according to claim 19, wherein said toxin is a diphtheria
2 toxin.

1 21. A method of reducing immunological rejection of transplanted
2 pancreas cells, said method comprising the administration of an effective amount
3 of a hybrid protein comprising 64K antigen, or an immunologic equivalent
4 thereof, together with a toxin.

1 22. A method, according to claim 21, wherein said toxin is a diphtheria
2 toxin.

1 23. A kit for the detection of evidence of diabetes in serum samples, said
2 kit comprising the following separately contained components: a 64K protein or
3 peptide or anti-64KA antibody; enzyme; and conjugated animal anti-human
4 immunoglobulin.

1 24. A kit for the detection of evidence of diabetes in serum samples, said
2 kit comprising the following separately contained components: radiolabeled 64K
3 protein(s) or peptide; wash buffers; and polyethylene glycol.

1 25. A recombinant microorganism or eukaryotic cell which has been
2 transformed so that it expresses a recombinant protein which is capable of
3 specifically binding with 64KA.

1 26. A recombinant microorganism, according to claim 25, wherein said
2 microorganism is an Escherichia coli.

1 27. A process for determining if the onset of insulin dependent diabetes
2 has occurred in a human or other animal, said process comprising determining
3 whether 64K autoantibodies are present in a sample of biological fluid from the
4 human or animal suspected of having insulin dependent diabetes, wherein said
5 process detects the occurrence of insulin dependent diabetes before β -cell
6 function has been substantially impaired.

1 28. A process for detecting the onset of insulin dependent diabetes before
2 substantial β -cell impairment, said process comprising the detection of
3 autoantibodies to a serine kinase of 64,000 M_r .

1 29. A gene coding for a serine kinase of 64,000 M_r , wherein said serine
2 kinase can be isolated from islet cell preparations and is associated with insulin
3 dependent diabetes.

1 30. A method for determining if the onset of insulin dependent diabetes
2 has occurred in a human or other animal, said method comprising the detection
3 of immune complexes comprising a 64,000 M_r serine kinase.

1 31. The process, according to claim 30, comprising the following steps:

- 2 (a) obtaining a sera sample from the human or animal to be tested for
- 3 insulin dependent diabetes;
- 4 (b) contacting said sera sample with immobilized protein A;
- 5 (c) labeling any serine kinase present with ^{32}P via kinase reaction; and
- 6 (d) detecting the presence of any labeled 64,000 M_r protein.

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AT	Austria	ES	Spain	MG	Madagascar
AU	Australia	FI	Finland	ML	Mali
BB	Barbados	FR	France	MR	Mauritania
BE	Belgium	GA	Gabon	MW	Malawi
BF	Burkina Faso	GB	United Kingdom	NL	Netherlands
BG	Bulgaria	HU	Hungary	NO	Norway
BJ	Benin	IT	Italy	RO	Romania
BR	Brazil	JP	Japan	SD	Sudan
CA	Canada	KP	Democratic People's Republic of Korea	SE	Sweden
CF	Central African Republic	KR	Republic of Korea	SN	Senegal
CG	Congo	LI	Liechtenstein	SU	Soviet Union
CH	Switzerland	LK	Sri Lanka	TD	Chad
CM	Cameroon	LU	Luxembourg	TG	Togo
DE	Germany, Federal Republic of	MC	Monaco	US	United States of America
DK	Denmark				